Publication | Closed Access

Chronic myeloid leukemia patients who develop grade I/II pleural effusion under second-line dasatinib have better responses and outcomes than patients without pleural effusion

Hematological MalignancyOncologyMixed-phenotype Acute LeukemiaSecond-line DasatinibHematologyPathologyPleural EffusionPleural DiseaseMedicineBetter ResponsesCancer ResearchMyeloid Neoplasia